GlassScriptPhysician profile
Robert T Hasbany
NPI 1760473094
$6,145.45
in general payments reported to CMS, 2019-2025
36 companies · $781 in 2025
The $781 reported for 2025 was more than what 81% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,371 · 2020: $1,169 · 2021: $731 · 2022: $536 · 2023: $716 · 2024: $841 · 2025: $781.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,338.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,338.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,153.49 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Pfizer INC. | $616.16 | 2019-2025 | |
| Glaxosmithkline, LLC. | $402.50 | 2019-2025 | Trelegy Ellipta |
| Horizon Therapeutics Plc | $360.97 | 2019-2022 | |
| Amarin Pharma, INC. | $293.52 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $238.20 | 2019-2023 | Trintellix |
| Abbott Laboratories | $235.08 | 2019-2024 | Freestyle Libre 3, Freestyle Libre 2 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $214.11 | 2019-2022 | |
| Exact Sciences Corporation | $176.22 | 2023-2024 | Cologuard Collection Kit |
| Eisai INC. | $166.39 | 2020 | |
| Janssen Pharmaceuticals, INC | $140.65 | 2019-2021 | |
| Abbvie INC. | $137.87 | 2019-2025 | |
| Medtronic, INC. | $115.39 | 2024 | Signia |
| Novo Nordisk INC | $109.41 | 2019-2021 | |
| Amgen INC. | $105.56 | 2019-2025 | Repatha, Otezla, Repatha |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shield Therapeutics INC | $73.39 | 2022-2025 | Accrufer |
| Bsn Medical INC | $72.38 | 2025 | |
| Vertical Pharmaceuticals, LLC | $68.27 | 2019 | |
| Edwards Lifesciences Corporation | $58.54 | 2025 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Allergan, INC. | $46.94 | 2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $45.00 | 2023 | |
| Merck Sharp & Dohme LLC | $35.50 | 2019-2020 | |
| Globus Medical, INC. | $33.26 | 2025 | Senza |
| Mdd US Operations, LLC | $32.85 | 2020 | |
| Medicomp INC | $30.84 | 2023 | Telepatch Cardiac Monitor |
| Kowa Pharmaceuticals America, INC. | $23.01 | 2020-2022 | |
| Therapeuticsmd, INC. | $20.36 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $18.45 | 2020 | |
| Lilly USA, LLC | $18.04 | 2021 | |
| Ultragenyx Pharmaceutical INC. | $16.93 | 2021 | |
| Astellas Pharma US INC | $16.73 | 2024 | Veozah |
| Otsuka America Pharmaceutical, INC. | $14.39 | 2023 | Nuedexta |
| Adlon Therapeutics L.P. | $14.37 | 2021 | |
| Idorsia Pharmaceuticals US INC | $14.19 | 2023 | Quviviq |
| Orexo US, INC. | $13.67 | 2019 | |
| Circassia INC. | $12.82 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Hasbany listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.